Sinovac Merely 50.4% Effective Against COVID-19 During Brazil Trial
SINOVAC TRIAL 50.4% EFFECTIVE – According to the latest data, China’s Sinovac vaccine had a 50.4% efficacy against COVID-19.
Sinovac has been amongst the most controversial COVID-19 vaccines in production. Medical experts heavily criticized the vaccine for being merely 50% effective against the virus. However, Brazilian researchers leaked premature data last week which showed the vaccine being 78% effective against the virus.
“We have a good vaccine. Not the best vaccine in the world. Not the ideal vaccine“, said researchers from Butantan biomedical center. But, the data revealed only showed its efficacy against “mild-to-severe” coronavirus cases.
However, they failed to include another group of “very mild” infections amongst those inoculated with the COVID-19 vaccine. As such, Ricardo Palacios, medical director for clinical research at Butantan explained the lower efficacy included data from “very mild” cases.
According to an article from Inquirer, the trials, researchers at Butantan had already delayed releasing their results three times. This was primarily due to a confidentiality contract with the manufacturers, Sinovac.
In the following month, the Philippines would receive its first doses of the COVID-19 vaccine form Sinovac. As such, netizens, frontliners, and medical experts raised concerns about its efficacy.
However, amid criticisms, Presidential Spokesperson Harry Roque emphasized that the public shouldn’t be picky about the vaccines. Meanwhile, LGUs had already closed deals to procure cheaper and more effective vaccines.
Thanks for reading. We aim to provide our readers with the freshest and most in-demand content. Come back next time for the latest news here on Philnews.
Like this article? READ ALSO: Sinovac Costs More, Less Effective Based On Data